Jump to:
Roquefort Therapeutics PLC Fundamentals
| Company Name | Roquefort Therapeutics PLC | Last Updated | 2024-11-22 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 135.737 m | Market Cap | £5.84 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.01 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.1004 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.2322 | Cash Equity Ratio | 0.1208 |
|---|
| Quick Ratio | 0.7917 | Current Ratio | 0.79 |
|---|
| Price To Book Value | 1.1841 | ROCE | 0 |
|---|
Roquefort Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Roquefort Therapeutics PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £50,152.00 | 0 | 0 |
| Intangible Assets | £5.34 m | £5.34 m | £1.48 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £5.39 m | £5.34 m | £1.48 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £157,589.00 | £101,738.00 | £2.18 m |
| Cash & Equivalents | £537,322.00 | £2.32 m | £899,721.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £6.09 m | £7.77 m | £4.56 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £307,114.00 | £279,670.00 | £195,517.00 |
| Creditors after 1 year | £281,911.00 | £281,911.00 | £281,911.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £589,025.00 | £561,581.00 | £477,428.00 |
| Net assets | £5.50 m | £7.21 m | £4.08 m |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £1.29 m | £1.29 m | £719,000.00 |
| Share Premium | £4.40 m | £4.40 m | £3.46 m |
| Profit / Loss | -£1.93 m | -£1.63 m | 0 |
| Other Equity | £5.50 m | £7.21 m | £4.08 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £5.50 m | £7.21 m | £4.08 m |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.2322 | 1.2322 | 1.2322 |
| Cash / Equity | 0.1208 | 0.1208 | 0.1208 |
| EPS | -£0.01 | -£0.02 | 0 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£1.73 m | -£1.58 m | 0 |
| Cashflow before financing | -£1.73 m | £1.52 m | 0 |
| Increase in Cash | -£1.79 m | £1.42 m | 0 |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | £200,000.00 | 0 | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | -£1.93 m | -£1.63 m | 0 |
Roquefort Therapeutics PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers. |
|---|
| Latest Interim Date | 27 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 26 Apr 2024 |
|---|
Roquefort Therapeutics PLC Directors
| Appointed | Name | Position |
|---|
| 2021-10-20 | Mr. Glenn Ross Whiddon | Non-Executive Director |
| 2024-04-26 | Mr. Stephen Paul West | Executive Director,Chairman |
| 2024-04-26 | Dr. Darrin Matthew Disley | Non-Executive Director |
| 2022-05-11 | Mr. Mark Andrew Rollins | Non-Executive Director |
| 2024-05-23 | Dr. Michael Stein | Non-Executive Director |
| 2024-04-26 | Ms. Jean Duvall | Non-Executive Director |
| 2024-04-26 | Dr. Simon Sinclair | Non-Executive Director |
| 2023-06-05 | Professor Sir. Martin John Evans | Non-Executive Director |
| 2024-04-26 | Mr. Trevor Ajanthan Reginald | Executive Director,Chief Executive Officer |
Roquefort Therapeutics PLC Contact Details
Roquefort Therapeutics PLC Advisors
